Business Context and Reporting Period
Company: Bone Biologics Corp
Filing Type: Form 8-K (Current Report)
Date of Report: June 10, 2016 (Event Date)
Reporting Period: Single event date; not a periodic financial report.
Key Financial Metrics
This filing is a current report regarding a material definitive agreement and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the entry into the Tenth Amendment to the License Agreement with The Regents of the University of California, effective June 10, 2016. Key terms include:
- Subject: Expansion of rights for "Nell-1," a recombinant human protein growth factor for bone development.
- Current Rights: Exclusive rights to develop and commercialize Nell-1 for spinal fusions.
- New Rights: An exclusive right to negotiate expanding the field of use to include the treatment of osteoporosis.
- Option Term: One year commencing June 3, 2016.
- Conditions: Exercise of the option requires completion of specific diligence milestones and subsequent good faith negotiations.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued on June 14, 2016, regarding the amendment but does not include specific forward-looking guidance or financial projections within this text.
Risks and Contingencies: The expansion of the field of use is contingent upon the Company meeting diligence milestones and successfully negotiating terms with The Regents. The filing notes that the description of the amendment is qualified by the full text of the agreement filed as an exhibit.
Investor Verification Checklist
- Verify the specific diligence milestones required to exercise the osteoporosis option.
- Review the full text of the Tenth Amendment (Exhibit 10.1) for detailed financial obligations or royalty terms.
- Confirm the status of Nell-1 development and commercialization for spinal fusions.
- Check for any subsequent press releases or filings regarding the exercise of the option.